Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group TrialAxel Le Cesne, Ole S. Nielsen, Isabelle Ray‐Coquard et al.|Journal of Clinical Oncology|2005Cited by 421
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular targetJaap Verweij, Ole S. Nielsen, A. van Oosterom et al.|European Journal of Cancer|2003Cited by 403
Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyPaul Lorigan, Jean‐Yves Blay, Jaap Verweij et al.|Journal of Clinical Oncology|2007Cited by 256
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphomaPier Luigi Zinzani, F. Morschhauser, Lionel Karlin et al.|Haematologica|2016Cited by 48